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Abstract
Although South Korea has taken various measures related to regulatory reform over the past decades, 
it has not made significant progress in transforming its regulatory framework. There are still a large 
number of regulations that are outdated and exist only in South Korea compared to other developed 
countries. This working paper reviews key measures made in recent years and clarifies critical steps 
that the country must take to make a successful transition. We first examine the direction of regulatory 
reform corresponding to the Fourth Industrial Revolution and how developed countries are rapidly 
moving to conceive the optimal regulatory design to promote innovation. Then, we highlight the major 
efforts South Korea has made in recent years to initiate regulatory reform and the fundamental 
challenges that remain. Lastly, we dive deep into regulatory reform for health care innovation, 
particularly as the government pledges to build a world-class bio-health industry over the next decade. 
We also approach regulatory reform from a public perspective, discussing how to encourage civic 
participation through open-minded communication and information-sharing with the public. As the 
South Korean society lacks trust towards new technologies and data usage, it is crucial to establish 
credibility of emerging industries as well as a balanced understanding of the potential benefits, ironing 
out conflicting views between stakeholders. 
Chapter 1: Global shift towards adaptive co-regulation in the post-pandemic era
Rapid advances in technology are disrupting and reshaping every industry and society in the 
era of the Fourth Industrial Revolution. Emerging technologies such as Artificial Intelligence, robotics, 
and the Internet of Things are driving the creation of new products, business models, platforms and 
solutions, from manufacturing and logistics to precision medicine, autonomous cars and virtual 
assistants. Also, the traditional notions of money and ownership, as well as labour and productivity have 
been radically redefined with the birth of cryptocurrencies, sharing platforms, automation and the gig 
economy. Economies can no longer rely on past methods of production, value creation and productivity 
as emerging technologies will serve as key drivers of economic growth and social development for 
generations to come in the “new normal” era of hyper-digitalization prompted by the novel coronavirus 
outbreak in 2020.
New technologies tend to develop faster than the regulations or social structures governing 
them, while carrying high levels of risk. Outdated regulations fail to support, and can even stifle, 
innovative research, products and the birth of new industries. Also, the unpredictable nature of the 
market as well as the valley of death present uncertainty for developers and businesses which is made 
all the greater by the absence of clear guidelines from authorities. Furthermore, unprecedented 
complexities arise from the impact of novel technologies on society and individuals, such as the 
automation of jobs, breach of personal information and privacy; as well as ethical questions that arise 
from developments in life science like gene-editing and the issue of liability in road accidents caused 
by self-driving vehicles.
In light of these new challenges, a 2018 KDI study edited by Lee and Choi (Lee, J. & Choi C., 
2018) identified the need for a systematic reform on how to regulate technology that breaks the 
boundaries of traditional technologies and the rules that govern them. First, we proposed ways for 
regulators to employ flexible approaches that encourage innovative activities, maximising the benefits 
while minimising negative externalities. Second, we prescribed a “regulatory innovation ecosystem” 
where all stakeholders of society would shoulder the burden of risk and uncertainty as well as ethical 
challenges surrounding emerging technologies. 
1. Fast tracking innovation: paving the way with innovative regulations
In our 2018 study, we proposed three different mechanisms governments could employ to make their 
regulations flexible and adaptive.
First is the introduction of a “negative system” based on ‘permissionless’ innovation. In  
South Korea, most statutes in a “positive” regulatory system are based on the precautionary principle, 
that lists what the law permits. As all activities without permission are banned, the regulatory 
environment is predisposed to being inflexible and preventive of new technologies, and also creates 
significant blind spots. The positive system is a supplier-oriented regulatory system, which is easy to 
manage and has a clear standard of punishment, but can lead to a significant increase in regulatory 
compliance costs for new business models and new markets where uncertainties exist. Therefore, 
adopting a looser and wide-ranging negative regulation system would allow greater flexibility in 
legislation, through a comprehensive definition of key terms and concepts, flexible classification, 
performance-based regulations, and the delegation of statutory powers to subordinate authorities.
Another approach is adopting a regulatory sandbox to enable maximum flexibility in testing 
new technologies and accelerate the process of commercialization. The regulation sandbox was first 
introduced in the UK to foster its fintech industry. It lays the legal groundwork for pilot projects 
where new technologies and business platforms can be tested freely and to their full capacity as all 
existing regulations can be ignored; or partially or temporarily waived within the boundaries of the 
sandbox. Many countries, including South Korea, Japan, China, and the United States, have also 
introduced regulatory sandboxes, with complimentary measures such as preliminary approval and 
post-regulation to emerging industries.
Third, we suggest a risk-based approach could be employed, following early impact and risk 
assessment. Regulators could respond and adapt to emerging technologies, introducing regulations 
only where needed, depending on the level of risk. Taking a case-by-case approach is advisable as a 
negative regulation system, for instance, doesn’t suit all industries or legislative contexts and 
adopting a universal policy approach would not provide the flexibility needed to support and regulate 
new forms of businesses. Thus, measures such as pre-regulation, ex-post regulation, interim 
regulation, administrative guidance, and non-regulation can be applied appropriately, following the 
assessment of the size and probability of risk for the technology in question. For technologies that 
fall into the “high risk” category, strict pre-regulation should be placed prior to commercialization, 
whereas the principle of free entry should apply for technologies that are considered to pose a lower 
level of risk. In the “low risk” scenario, self-regulation can be implemented while traditional 
regulators can strengthen oversight, re-evaluation of risks, and apply ex-post regulation where 
needed. 
2. Innovation Ecosystems as a Regulatory Framework
Innovation is no longer confined to the laboratories of corporate giants or government 
institutions, nor is it commissioned under controlled environments and top-down initiatives. The 
world has been experiencing a democratisation of innovation and technology, through lower costs of 
technological tools, greater access to information, ideas and networking as well as crowdfunding 
(Cohen B. and Munoz P. 2016). 3D printing, for instance, allows anything to be printed and 
distributed from thousands of miles away, from auto parts to drugs and, potentially, human organs 
for transplantation which are now undergoing clinical trials. Now, countries that are leading the 
development of emerging technologies have a healthy landscape of innovation ecosystems which 
bank on the close proximity and availability of strong university research, entrepreneurial landscape 
and a quality talent pool, which are interlinked in a continuous virtuous cycle. The most prominent 
examples of this bottom-up innovation can be found in Silicon Valley in the U.S. and Tel Aviv in 
Israel which produce some of the world’s most cutting-edge technologies and largest IT companies 
in the world. 
While the innovation ecosystem is not a new phenomenon, our study in 2018 broadened the 
definition to include ‘inclusive regulatory innovation,” meaning that collaboration between industry, 
researchers, business actors and civil society is not limited to creating business models, platforms, 
products, and industries. Stakeholders of the ecosystem should also come together to design optimal 
regulations to encourage innovative research and development while addressing societal, 
environmental and ethical concerns. This requires discourse and cooperation from all sectors and a 
society-wide shift to a “regulatory culture” (Lee J. and Choi C. 2018).
The case for shared regulation between government, businesses, and civil society has been 
growing strongly in recent years, as digital technologies and services blend the public and private 
spheres. Governments are being called upon to provide more efficient public services and show 
greater transparency through digital communication and online government systems. Businesses 
have become co-facilitators of public governance, developing and leveraging their technologies to 
accomplish public goals (OECD 2011). Meanwhile, the role of citizens has evolved from simply 
consuming mass manufactured goods and services to becoming part of the value creation process in 
the connected, digital economy. As “prosumers” of on-demand, personalized services, sharing 
platforms and data-driven services, members of the public are shaping and driving industries with 
the consumption and lifestyle choices they make. Therefore, their greater civic commitment and 
participation can better inform and shape regulatory design, and help reduce uncertainties for 
innovators while also consolidating consensus on new social challenges. In 2018, the UK’s Digital 
Charter brought together the government, the tech sector, and businesses and civil society to jointly 
address the challenges of digitalisation and find relevant solutions. 
While the above suggestions were made in the context of South Korea’s regulatory environment, 
they have remained strongly relevant as guidelines for any government to build the optimal regulatory 
framework to respond to emerging technologies.
The World Economic Forum in 2018 described this as a form of “agile governance” in the Fourth 
Industrial Revolution Era, highlighting the importance of collaboration between policymakers, industry 
and citizens in jointly designing regulations that are adaptive, inclusive and sustainable. The United 
Kingdom in 2019 laid out a similar regulatory framework to support its Industrial Strategy (2017) which 
commits to hefty investment in life sciences, AI, robots, technical institutes and to boosting earning 
power. UK aims to: adopt agile and outcome-based regulatory measures such as the use of voluntary 
standards, innovation testbeds; stronger public engagement; streamlining regulatory bodies by 
establishing a new council to oversee regulations and institutions; supporting innovation ecosystems by 
enhancing research and development (R&D) and nurturing a talent pool through more adaptive 
education. The European Union and Japan’s Society 5.0 and New Economic Policy Package (2018) 
have also identified the need for flexible, adaptive regulations to harness the core future technologies.
This paper aims to review how far South Korea has progressed in terms of reforming its 
regulations to accommodate key areas of innovation, based on the recommendations we made in 2018. 
In the next two chapters, we examine the regulatory changes that have taken place in the South Korean 
context since 2018, based on recent data and publications along with interviews we conducted with 
industry experts, developers and innovative businesses directly involved in regulatory changes. Chapter 
Two will review efforts to promote the development of major emerging technologies and the utilization 
of data which is considered the lifeblood of the Fourth Industrial Revolution. In Chapter Three, we will 
focus on the bio-health sector, as a key sector in most pressing need of reform, especially as it is 
crucially needed to overcome the burgeoning challenges to public health and it was, this year, 
designated as a pivotal growth engine under the government’s economic strategy. The final chapter will 
set out basic guidelines on laying the groundwork for a bottom-up innovation ecosystem, based on our 
previous recommendations, and taking into consideration the recent regulatory developments and 
challenges.
Chapter 2: Can South Korea break out of the box?
At the turn of a new decade, South Korea has drawn up a brand “New Deal” to revitalize its 
economy and renew its technological prowess as a leading global innovator. With over $130 billion 
earmarked for the initiative, much of the deal will focus on building new engines of economic growth 
through innovation in the digital and green sectors, mostly in the form of contactless, data-driven services. 
Over the past five decades, the country has made an astronomical leap from a post-war economy producing 
textiles and plywood to manufacturing cutting-edge digital devices and semiconductors, and biosimilars. 
Its accomplishments have received much accolade from the global community, with Nature Index 2020 
even dedicating a special edition that highlighted the country’s top-down innovation that produced the likes 
of Samsung, LG Electronics and SK Hynix.
However, amid the Fourth Industrial Era, South Korea’s traditional cash cow industries such as 
semiconductors, automobiles and shipbuilding are waning in value and competitive advantage, as global 
competitors are rapidly catching up and new value chains are being created. As new, game-changing 
technologies emerge, and become broadly established and adopted across the world, it has become crucial 
to become a first mover in order to become the industry standard-bearer and leverage the network effect, 
given the winner-takes-all nature of the global tech market. Governments everywhere are rising to the 
challenge, having set out their respective industrial strategies for emerging technologies, and most crucially, 
new regulatory frameworks that are agile, flexible, and responsive which promote competition and 
innovation.
South Korea has not been able to respond rapidly to the changing global dynamics. Despite the 
explosive nationwide hype over Artificial Intelligence triggered by the historic showdown of Go player Lee 
Se-dol and Deep Mind’s AlphaGo in 2016, there has been no concrete national strategy for AI until 
December last year, far behind countries like the United Kingdom and Japan. There have also been no 
South Korean killer apps or platforms taking over the global market like Netflix and TikTok, nor has the 
country yet to boast of future cars like Tesla or Nikolo. In medicine, South Korea excels in producing 
biosimilars, with production capacity second in the world after the U.S. and the country received global 
attention in 2020 for its rapid development of COVID-19 test kits after the first local infection case was 
reported. However, no blockbuster drug, or ground-breaking health care device has emerged from the 
country and, as lamented every year, South Korea has yet to see a Nobel Prize-winning scientist.
The lack of progress is disappointing, considering the country’s highly-educated workforce, large number 
of patent filings and sizeable investment in research and development (R&D) the scale of which is second 
after Israel in scale relative to gross domestic product (GDP), and a series of attempts by one administration 
after another to grow a vibrant landscape of start-ups. Compared to Israel’s Tel Aviv, which is considered 
the world’s sixth major start-up ecosystem after the iconic Silicon Valley, Seoul only made the Top 30 this 
year (no. 20), primarily for its strength in R&D.
For years, experts have pointed to regulatory barriers, a lack of ecosystem coordination, based on a “positive 
regulatory system” as key factors that have stifled creative research and the development of novel 
technologies and solutions. This has subsequently compromised the country’s global competitiveness in 
emerging industries (Lee J. and Choi C. 2018), causing the country to fall further behind in the race to 
develop Fourth Industrial Revolution technologies. The World Competitiveness Ranking scored South 
Korea at 28th place in 2019, with government efficiency falling by two places from 29th to 31st.
In order to overcome this critical government failure, we believe a regulatory ecosystem must be established, 
in line with our recommendations made in 2018. We propose a systematic overhaul of the current regulatory 
system that inhibits competition and innovation, an independent control tower to spearhead regulatory 
innovation, along with improved support for start-ups, and a platform for social deliberation and consensus.
CURRENT GOVERNMENT INITIATIVES 
Over the past 4 years, both industry and academia have called for the government to ease its 
outdated regulatory regime characterized by “positive regulations” and an overbearing bureaucracy, which, 
together, have imposed a culture of risk aversion, rather than promote and reward innovation.
Centered on the ‘‘precautionary principle,’ positive regulations only allow listed or stated activities in 
developing new technologies, thereby outlawing any activity that has not been permitted by law. This white-
list approach makes it infeasible for innovative activities to take place, from the stages of research to 
commercialization, as they do not fit into the realm of existing regulations. For instance, South Korea’s 
laws on road safety and the environment, for instance, currently do not recognize robots as a vehicle, thus 
effectively bans them from being tested or used on public roads as delivery devices. Privacy regulations 
also limit the development of self-driving technology. Camera footage is crucial to helping unmanned 
mobility devices detect, identify and remember the environment around them. However, under current 
regulations, video cameras cannot record people’s faces or any attributes that could identify an individual. 
Other key areas of emerging technologies are similarly hindered by such outdated regulations, not only in 
the stages of development, but also commercialization that could grow whole new industries. For instance, 
restrictions on using Direct-to-Customer (DTC) genetics test kits have hindered local companies from 
developing products like ‘23 and Me’ which could benefit personal, preventative health care and even grow 
an entire gene-based industry around it, from DNA-based meal services and cosmetic products.
The government has implemented several measures we recommended (Lee J. and Choi 2018), such 
as adopting a regulatory sandbox and introducing legislative revisions to fast-track reviews on new medical 
technologies. It has also implemented the revised ‘three data laws’ in August 2020, after years of 
parliamentary gridlock.
Key changes in ‘3 Data Laws’
Personal Information Protection Act (PIPA)
Clarified concept of ‘personal data,’ and ‘pseudonymized data’ and removed anonymized data from 
the scope of personal data).
Clarified the scope of permitted processing of pseudonymized information:
1. Allowing use of pseudonymized data for statistical, scientific research, or public interest 
record-keeping purposes
2. Allowing pseudonymized data to be combined through specialized agencies.
● Imposed new restrictions upon pseudonymized data processing.
● Allowing use and transfer/release of personal data without obtaining consent, if the purpose 
is related to the original purpose of data collection.
● Enhanced the Personal Data Protection Commission (PDPC)’s authority and powers.
Network Act
● Removed provisions related to the protection of personal data to prevent overlap with PIPA.
● Provided a legal basis for delegating partial authority to the South Korean Communications 
Office from the South Korean Communications Commission (KCC)
Credit Information Act
● Clarified the legal basis for analysing and using big data in the finance sector.
● Streamlined legal framework to minimize overlaps with provisions under PIPA.
● Introduced MyData platform (providing consolidated-basis personal information verification 
and credit information and/or asset management)
● Strengthened the protection of personal data in the finance sector.
Regulatory Sandbox
South Korea’s regulatory sandbox took effect in January 2019, as a two-year mechanism for 
exempting or suspending regulations on new technologies to develop goods and services that were 
previously unavailable due to such rules. The aim is for businesses test and optimize their 
technologies and services in a controlled environment, or a limited market, while the government 
can swiftly improve related regulations based on real-life data. The sandbox period can be extended 
once. 
However, without fully embracing a regulatory framework that is conducive to innovation, the 
changes have largely remained cosmetic. Firms within the sandbox are still required to go through lengthy 
legal reviews to check for regulatory barriers. Upon discovering legal ambiguities, they must apply for a 
temporary waiver or special exemption for demonstration. As the long and complex approval procedures 
hinder business for participating firms, they are grappling with lost time and growing maintenance costs, 
making it uncertain whether they will be able to take their products to market by the time their sandbox 
period expires, or whether they can keep afloat as a business. There is also growing concern and doubt on 
whether authorities are willing to change regulations given the blame avoidance culture (Seoul Economic 
Daily 2020).
Meanwhile, the country’s revised data laws have also generated scepticism over whether it can 
create a multibillion dollar ‘data dam’ that will fuel innovative products and services. The majority of firms 
remain cautious about processing and utilizing data, as the recent revisions have not provided sufficient 
clarity on major sticking points, such as the additional usage of data and the acceptable standards of 
pseudonymization particularly in key technologies like video processing for self-driving cars. Also, 
stringent terms on punishing violation cases add to their nervousness around using data (Kim 2020).
In 2019, a survey of 500 companies found 30.6 percent were pessimistic about the impact of the 
administration’s recent regulatory reforms, which double the proportion of optimists (15.6 percent). The 
responses were the opposite of the 2018 survey results where 32 percent were optimistic while 10.6 percent 
were pessimistic (KERI 2019). More than a third of the firms that were dissatisfied with regulatory reform 
cited “insufficiency in resolving invisible barriers and blind spots,” “lack of regulatory improvement,” 
unwilling attitude among public servants” and the “creation and strengthening of regulations.”
In the academic realm, the government holds excessive control over research and development, 
discouraging autonomy and creativity of the scientific community. By interloping in the innovation process, 
from deciding which technologies, products, or researchers to support, it is difficult to see the kind of 
bottom-up innovation that takes place in Israel where the country’s Chief Scientist formulates the 
framework of scientific and industrial R&D. According to a survey of 75 members of Korean Academy of 
Science and Technology, only 22.6 percent of all respondents were satisfied with how the government 
selects and evaluates R&D projects. More than half the respondents believed bureaucrats showed 'bias in 
project planning,’ 'unclear standards of evaluation,’ and ungrounded ‘restrictions on participation’. As civil 
servants themselves are evaluated according to the quantity of their achievements, they tend to select short-
term projects that would deliver maximum performance (Song 2020).
Case: Regulatory Sandbox
The regulatory sandbox was adopted in January 2019, to allow new products and services to be tested 
and developed under a controlled environment, until regulatory adjustments are made if the 
technology is deemed appropriate for use. Firms can extend their 2-year period once, allowing them 
a total of four years inside the sandbox.
Source: Ministry of Trade, Industry and Energy (2019)
Upon the one-year mark of introducing the sandbox, the government had approved 239 new products 
and services to be tested within the system including 47 cases in ICT, 52 cases in convergence 
industries, and 102 cases in the financial sector. However, even with the regulatory sandbox in effect, 
strong uncertainty remains for developers (Jung 2020). Firms are complaining there are just as many 
barriers within the sandbox, as they need to acquire additional approval to test technologies that 
breach or contradict existing laws. This means developers must still devote a large amount of time 
reviewing regulations to determine whether they are breaking any laws, and whether they need to 
apply for a special permit to test their products (Moon 2020). For instance, self-driving robots need 
to acquire special permits from the transport ministry to drive their devices across parks and green 
spaces, as mobility equipment over 9 kilograms is banned from entering green spaces.
Also, developers face growing costs and uncertainty as they wait for approval to test or roll out their 
products. DTC genetic testing firms, for example, must gain the Institutional Review Board’s 
approval for each and every type of health indicator their test kits can offer consumers, such as the 
level of Vitamin D in their system or the level of genetic disposition to contracting certain diseases. 
While these services require no such approval in countries like Belgium, Canada and the UK, the 
firms inside South Korea’s sandbox must go through multiple review procedures, to obtain all the 
permission and clearance they need to test their technologies. One of the biggest firms inside the 
sandbox, Macrogen, has gone through five review procedures yet only received permission to test 6 
out of the 24 indicators it sought approval for more than a year, as more and more regulatory issues 
kept surfacing (Lee 2020).
The focus should not be about the number of firms entering the sandbox but what comes out of it. 
Start-ups are uncertain whether they will be able to sustain themselves financially until they receive 
clearance for the technologies they need to test. Another major point of concern is whether the 
government would revise regulations accordingly, and in a timely manner, by the time the sandbox 
period expires.
POLICY RECOMMENDATIONS
In order to shift from a “fast follower” to “first mover,” an ecosystem approach to be at the heart 
of South Korea’s regulatory design (Lee J. and Choi C. 2018). We maintain our 2018 recommendations on 
building a pro-competition and pro-innovation regime, with the government transforming its role from a 
controller to enabler of innovation.
First, there needs to be an effective decentralization of regulatory powers, bestowing more 
autonomy and authority to industry experts and research intermediaries when it comes to .designating 
Starting with R&D, the government should step back from its excessive involvement in every stage of the 
innovation process, from designating research priorities to selecting projects and participating firms. Instead, 
we suggest regulators enhance autonomy of intermediaries that will facilitate “high-risk/high-payoff” 
projects, based on a competitive selection process of R&D areas and research partners. Delegating highly 
qualified field specialists and industry experts would allow for more informed and efficient measures to 
support the growth of new technologies and industries, which are rapidly evolving and changing according 
to market demand. As seen in the United States’ Defence Advanced Research Projects Agency (DARPA), 
hiring technically-accomplished experts as program managers who have the authority and responsibility to 
propose and implement R&D programs has been the backbone of the country’s world-class innovations 
(Bonvillian et al. 2019). The managers determine the scope, rationale and technologies as well as the metrics 
of measuring progress and budget for each project, which is facilitated by outside labs, experts and firms. 
Breakthrough technologies discovered in the process such as robotic arms to handle explosive content have 
led to the most widely used commercial technologies today including the Global Position System (GPS) 
and Apple’s voice assistant Siri.
Also, in terms of both R&D and commercial practices, the government should accept industry standards 
and enable self-regulation, especially in data usage. As mentioned in the previous chapter, most scientific 
communities have established their own standards and principles which outpace government-drafted 
regulations as they adapt faster to changes in technology, market and industry. Therefore, it is more efficient 
to entrust expert communities with establishing the rules, which would not only save bureaucratic time and 
resources but also develop trust between industry and government and increase likelihood of compliance. 
Furthermore, as businesses tend to respond more rapidly and sensitively to market demand, it is in their 
interest to develop products and practice standards that benefit consumers and are socially responsible. 
Thus, rather than trying to set the rules, the government should rather focus on reviewing and overseeing 
compliance to ensure societal interests are met, and supporting consumer and citizens’ rights.
Second, a permanent control tower is needed as a hub and constant driver of regulatory innovation 
(Lee J. and Choi C. 2018), conducting oversight and coordination over decentralized regulatory forces as 
mentioned above. While there are currently several executive committees and government bodies dedicated 
to regulatory reform their roles and powers have been sensitive to political changes, limiting their scope 
and capacity to pursue long-term strategies for innovation. The Regulatory Reform Committee, for instance, 
has been subject to downsizing and expansion, depending on the administration. In 2005, it made 367 cases 
of recommendations but only 40 cases in 2016. In 2000, 94 withdrawal recommendations were only 4 in 
2015 and 2016. Also, its membership is mostly limited to government ministers, and a panel of experts 
from economic or legal backgrounds, who only convene when an agenda is raised. The Prime Minister’s 
office has its own Regulatory Reform Office, which plays a key role in reviewing thousands of proposals 
received from central government bodies. However, it has been understaffed for years, and is also subject 
to political changes. Thus, it has been systematically difficult to promote long-term regulatory reform tasks, 
let alone accumulate sufficient know-how necessary for regulatory reform within the given term. While the 
Fourth Industrial Revolution Committee, which was established in 2017 with the purpose of shaping and 
leading the advancement of emerging technologies, it has been criticized for its failure to coordinate 
innovation policies across government ministries, as well as its lack of initiative on regulatory reform in 
key areas such as mobility platforms and artificial intelligence. The committee was also blasted for the
frequent absence of ministers at committee meetings, marking only a 25 percent attendance rate (Choi I. 
2020).
Given these constraints to the consistency of reform, we propose establishing a permanent and independent 
reform committee within the government to coordinate and drive regulatory changes, irrespective of the 
political environment. The organization should oversee the review of pertinent regulations, consult 
government bodies, and, most crucially, plan and initiate priorities and long-term strategies for regulatory 
reform. To ensure its neutrality and accountability, an organization should be able to allocate its own budget 
to effectively and appoint personnel independently and competitively. A number of advanced economies 
have already set out to establish such an institution for regulatory reform. Germany’s Nationaler 
Normenkontrollrat was established in 2006, while the UK set up its own Regulatory Policy Committee in 
2009. The U.S. also installed the Office of Information and Regulatory Affairs (ORIA) for more stable 
regulatory management, within the Office of Management and Budget (OMB). In 2015, the European 
Union also conducted a Regulatory Scrutiny Board (RSB) was installed to strengthen the independence and 
accountability of regulatory reform agencies (Lee M. 2017). These cases demonstrate the necessity of 
making regulatory reform committees permanent and visibly independent to ensure that there is neither 
short-term political interference nor any type of bias or favouritism towards or against particular players 
(Bew P. 2016).
A new regulatory reform committee would also require greater diversity of participants to enable an 
efficient, democratic regulatory ecosystem. Regulators should actively engage with representatives of 
industry, experts, and civic groups to include them in process of regulatory reform and encourage positive 
attitudes towards compliance. In this regard, the body should broaden and strengthen cooperation with 
expert groups and research institutions such as Korea Development Institute, where policy professionals 
are already conducting extensive research on regulatory reform and innovation. The involvement of 
research institutions could contribute significant value in the regulatory reform process, not only providing 
high technical support in analysis and design but also serve as neutral actors which is likely to enhance 
public trust and confidence (OECD 2017).
Third, public deliberation must become a core, established part of regulatory reform, especially in 
the era of the Fourth Industrial Revolution, where the benefits of technology are expected to trickle down 
to the individual with increasingly intelligent, connected, and personalized solutions. At the same time, new 
risks have surfaced in privacy, cybersecurity and jobs, as emerging technologies are largely driven by data 
consisting of personal information and enable the automation of traditional human jobs. Thus, it is vital to 
include citizens when addressing fundamental questions such as: whether or to what extent new 
technologies should be adopted; who would benefit or become disadvantaged as a result, and what ethical 
concerns would arise from such technologies.
However, in South Korea, civil society has rarely been part of the debate concerning emerging technologies. 
The most outspoken groups influencing regulatory design have been businesses, labour unions and activist
groups who are strongly inclined to resist new technologies and changes in the market. 
As the wider population has been grossly unrepresented, regulations have become misaligned with public 
sentiment and consumer demand leading to both government and market failure. The country has not been 
short of such examples – the mobility sector being the most notoriously affected. For instance, an 
overwhelming number of South Koreans chose to use carpool app Tada, which garnered 1.7 million users 
before parliament passed a bill to outlaw it in March 2020. However, the users’ needs for an affordable 
carpooling service was not taken into consideration and the government heeded the voice of taxi unions 
before deciding to ban the service from operating. It is the same situation with the question of adopting 
telemedicine in South Korea. Despite the growing need for affordable and accessible medical care, and the 
largely positive response from patients who have used telemedicine, the debate is being dominated by 
doctors’ unions who fear technology will dislodge their profit model and introduce new competitors.
Thus, it is crucial to include civil society as part of a regulatory innovation ecosystem. Regulators must 
commit to public engagement and build it in a way that reaches beyond traditionally interested groups and 
individual; and seek to connect with people from all walks and backgrounds. In addition to advancing 
democratic deliberation, the participation of the public could help rationalize and strengthen the case for 
regulatory changes in sensitive issues, especially in a country like South Korea where issues are heavily 
politicized or skewed by interest groups. In the UK, innovation-related authorities held over 20 roundtables 
across the country, involving over 250 organisations to form the government’s National Data Strategy in 
2019. Through the process, the government engaged with academics, civil society, small and medium-sized 
enterprises and public sector organisations. The findings from these roundtables became the basis for the 
UK’s strategy and regulatory design for emerging data-based technologies (Roberts 2019).
Given South Korea’s advanced digital infrastructure and high accessibility to social media platforms, there 
are many ways to inform and encourage citizens to assume their role as a stakeholder in the innovation 
ecosystem. We believe this should be achieved through public deliberation in the following ways:
First, in order to increase citizen participation in the process of regulatory reform, it is necessary to 
determine who should decide the contents of regulation and the method of enforcement; the relationship 
between these actors, and how their interests and conflict structures are organized. Especially with the 
increasing use of social media and platform-based services, in which consumers are also becoming part of 
the value creation process, it is difficult to accurately grasp the power relations between corporations and 
citizens; and determining what should be subject to regulation. Therefore, the agenda should be raised by 
the citizens themselves, through a bottom-up, deliberative process, as part of regular discussions with 
industry experts. As a result of these interactions and potential relationships formed in the process, the 
discussions could generate collective intelligence that not only inform the experts of public opinion but also 
provide opportunities for mutual learning, understanding and empathy, leading to a higher level of social 
integration (Lee J. and Choi C. 2018).
Second, the scope of these discussions should be unlimited and distinguished from government-led 
and expert-oriented discussions -- the bounds of which are constrained to set agendas and 
formalities. However, as a prerequisite to such citizen discussions, it is necessary to improve public 
understanding and literacy of regulatory issues, overcoming the asymmetry of information. In order to 
transparently and accurately convey relevant facts to citizens, it is necessary to clarify specialized terms, 
concepts and expressions, and provide content and audio-visual materials in various formats, such as 
storytelling and infographics. In other words, civic and political literacy must be cultivated simultaneously, 
in order for citizens to holistically examine the interconnectedness of various issues and factors at hand, in 
the process of developing social issues into a regulatory agenda.
Third, previous studies have shown a perceived opportunity cost of citizen-perceived participation 
as one of the factors influencing the awareness and evaluation of each citizen participating in the democratic 
process (McAdam, McCarthy, and Zald 1996). In other words, for citizens to participate in debate and for 
society to develop rational democracy, it is necessary to establish a system of recognition and evaluation 
that citizens have less social and economic burden. Therefore, in the institutional system, it is necessary to 
efficiently manage the cost of public discussion and communication, and to establish an economic process 
so that this approach can positively affect citizens' participation in discussions and policy deliberation. As 
such, for the policy process of a more mature civil society, it is necessary to increase the social responsibility 
of the participants by clarifying the scope and limitations of the confidentiality of the policy information 
disclosed in the discussion.
Fourth, public forums should be designed to stimulate and leverage interpersonal communication, 
as a strategic approach. By forming relationships and stirring creativity among participants, the discussions 
should trigger the individual's intellectual flexibility and enable rational communication between groups, 
leading them to engage in meaningful dialogue actively and creatively, and generate collective intelligence. 
This is vital in the context of the South Korean society which remains rigid and conservative towards public 
debates and open discussions. It may perhaps be necessary to prepare measures to prevent Confucian values 
and common psychological mechanisms from being ignited and hindering the deliberative process.
As South Korea looks to bolster the development of contactless technologies and services, as a means of 
recovering from the COVID-19 crisis, building a digital public forum could mark a promising start for 
greater public dialogue. A new culture of digital discourse could be fostered, helping overcome the 
traditional social mechanisms such as indirect communication and vertical collectivism.
South Korea can no longer rely on its top-down approach to economic growth, amid constantly 
changing dynamics of a hyper-digital world and a winner-takes-all market. To move forward and unlock 
the benefits of the Fourth Industrial Revolution, an ecosystem is needed to propel the country’s status of 
fast follower to a first mover in the global market. However, without fundamental changes to regulatory 
framework, South Korea cannot make the transition.
CHAPTER 3: BUILDING BIO-HEALTH INNOVATION ECOSYSTEM
The novel coronavirus outbreak of 2020 has highlighted the strong capacity and flexibility of South 
Korea’s medical innovation, as local firms quickly developed highly efficient rapid test kits and rolled out 
high-tech digital solutions to trace and isolate those infected. The international accolade and demand for 
South Korean bio-health products has given rise to wide anticipation that the country will embark upon a 
golden age of bio-health, which comprises medicines, medical devices and health management services. 
The current administration has laid out this aspiration in its 2020 New Deal strategy, and strategies on 
nurturing ten core industries for future economic growth. 
Going forward, South Korea stands at a critical juncture as the world shifts towards ‘precision 
medicine’ with the goal of 4Ps: preventive, personalized, predictive and precision medicine. Faced with the 
mounting costs of accommodating a rapidly ageing population and increasing cases of chronic and mental 
illnesses, a growing number of countries including the U.S., UK, China, and those in the European Union 
are focusing on developing key breakthrough technologies to treat severe illness, find cures for rare diseases, 
and overall, improve public health and well-being. The development and deployment of these medical 
innovations are expected to proliferate with the infusion of AI, Big Data, connected devices and blockchain 
technology. The Human Genome Project, for instance, which incurred 2.7 billion dollars and took 13 years 
to complete. However, genome sequencing cost less than 1,000 dollars in 2017 and took less than 48 hours, 
(Ministry of Health and Welfare 2019). In this way, advancement in emerging technology is helping make 
medicine much more precise, accessible and cost-efficient than ever before for overstretched health care 
systems everywhere. Not only that, but new bio-health technology is highly lucrative, expected to outpace 
the market growth of traditional industries such as automobiles and shipbuilding (Ministry of Health and 
Welfare 2019). 
Amid competition in a winner-takes-all landscape, regulatory flexibility is needed for innovators 
to test new ideas, technologies and products that lead the ‘biological century’ as coined by the World 
Economic Forum (WEF 2018). Efforts require more than seizing the momentum and the usual combination 
of investment and support for major industry players. This is especially true for South Korea has shown 
astonishing adeptness in “fast followership” in developing biologics and medical devices, ranking the 
world’s second and ninth in market share respectively (MDFS 2020). However, the country falls behind in 
innovation, with the patents and breakthrough findings rarely producing commercial success. Only one out 
of 150 major global start-ups in bio-health is in South Korea, according to CB Insights. Medical innovation 
in the country has been limited due to a restrictive regulatory culture, fragmented efforts in R&D and lack 
of risk funding to enable developers to cross the Valley of Death (KHIDI 2020).
In 2018, Scientific American’s Worldview report evaluated 54 nations’ competitiveness in the biotech 
sector, evaluating seven categories: productivity, intellectual property (IP) protection, intensity, enterprise 
support, education/workforce, foundations, and policy & stability. South Korea ranked 26th, down from 
24th in 2016. By category, it ranked first in terms of infrastructure, as in 2016, but scored lower (6.2 out of 
10) in Policy and Stability, which measures the competitiveness of government efficiency, regulation, and 
law. Korea's intellectual property rights protection competitiveness was also relatively low, scoring 5.1 out 
of 10.
In order to shift gears from fast follower to innovator in breakthrough bio-health technology, regulatory 
reform is needed. A new regulatory framework must lay the groundwork for steadfast, systematic, and 
system-wide support from basic research to regenerative medicine. 
1. GOVERNMENT INITIATIVES 
A. SOUTH KOREA’S NEW DEAL
South Korea Biologics firms in the country, led by Samsung Bioepis and Celltrion, have the 
capacity to produce around 520,000 liters of drugs per year, coming second to the U.S., and filing the third 
highest number of patents related to biopharmaceuticals (MDFS 2020). As of June 2020, 29 new drugs 
have been developed in South Korea with an average of two to three new drugs hitting the market every 
year. The country is also an active exporter of medical devices, ranking 9th in the world as of 2018, mostly 
for its ultrasound imaging systems, dental implants, and soft contact lenses. Exports grew 14.1 percent on-
year, hitting US$3.6 billion (KHISDI 2020).
The government in 2019 revealed a ten-year plan for 2030, by which they aim to triple the country's 
share of new medicine and health devices in the world market to 6 percent from the current 1.8 percent. 
Under the plan, South Korea will aim to hit 50 billion dollars in bio-health exports and create over one 
million jobs in the process.
The specific goals include:
- Building five major Big Data platforms to spur advancement in the bio-health industry, based on 
the data of 1 million people by 2029
- Creating new drugs and medical devices by expanding government spending in R&D to $3.3 billion 
by 2025
- Injecting more than $1.6 billion into establishing an ecosystem and funding for firms in form of 
financial subsidies and tax benefits
The current administration reaffirmed the administration’s commitment to this plan in 2020, highlighting 
bio-health, future cars and system semiconductors as three core engines of future growth for the South 
Korean economy. Particularly with the rapid digitalization of core services, South Korea’s ‘New Deal’ also 
commits to the use of data and AI in core industries including bio-health as well contactless services, 
alluding to telemedicine which is currently banned in the country.
Furthermore, the trade, health, science, and drug safety ministries in May announced they would begin a 
joint medical device R&D project worth 980 million dollars over the next five years. The pan-government 
effort would aim to develop core components and foundational technologies to create ground-breaking 
innovations, and roll out regulatory support to spur such developments.
B. REGULATORY REFORMS ENACTED BY LAW
After years of heated parliamentary debate, key regulatory reforms were made last year with 
legislation passed to promote the growth of bio-health industries. We first proposed and laid out the 
blueprint for these acts in 2017 (Lee J. and Choi C. 2018), as crucial instruments in paving the way for key 
medical technologies and discoveries to be made in the country.
1) Regenerative Medicine Act
First proposed in Dec. 2015, the Regenerative Medicine Act was finally enacted in 2019 and goes 
into effect from August 2020. By streamlining overlapping regulations related to biopharmaceuticals 
which were scattered across the Pharmacy (or Pharmaceutical Affairs Act) law and Bioethics and 
Safety Act, the act paves the way for conducting clinical research on advanced regenerative medicine 
(cell therapy, gene therapy, tissue engineering therapy, and etc.), which faced long and grueling 
approval procedures in the past. First, the act defines the categories of regenerative biomedicine as 
cell therapies, gene therapies, tissue engineering systems, and combination products. In particular, 
when certain requirements are met during clinical research on regenerative medicine, the act 
introduces a rapid approval and delivery system such as customized review, accelerated approval, 
and conditional approval; and establishes a safety management system. These fast-track would enable 
a speedier review process for regenerative medicine, prioritizing them above other drugs, and in case 
of severe illnesses like cancer or rare diseases, the product could be delivered to the patient based on 
phase 2 clinical data -- before the efficacy is confirmed by the phase 3 clinical trial. The law 
introduces a comprehensive safety management system for the development of advanced 
biopharmaceuticals and equipment, from the stages of cell collection to commercialization, as well 
as enforcing long-term follow-up investigations.
As a result, the process of developing regenerative medicine can be reduced by three to four years.
2) Innovative Medical Devices Act 
The Innovative Device Act, which went into effect in May 2020, lays out a separate premarket 
pathway for the research, development and commercialization of novel medical devices and 
technologies. It introduces a certification system for "innovative medical device companies" which 
can enjoy greater state support and opportunities to participate in government projects as well as tax 
incentives. Also, “innovative devices” can undergo a simplified review and approval process which 
include exemption from certain pre-approval requirements. The act also sets out a separate safety 
management and support system for such innovative medical ventures, separate from the Medical 
Devices Act.
3) In Vitro Diagnostics (IVD) Act
The IVD Act was enacted in light of views that IVDs should be regulated separately from other 
medical devices since they are only used for diagnostic purposes and do not come in contact with the 
human body. The act aims to expedite market authorization and provide greater support for IVDs, 
based on a four-level labelling system that weighs the purpose of use, and the potential risk it has on 
individual and public health.
In addition to these changes in medical regulation, the National Assembly also revised three key 
data laws in early 2020, with the purpose of allowing ‘pseudonymized’ information to be collected and 
transferred to third parties, under the revised Personal Information and Protection Act (PIPA).
Personal Information Protection Act (PIPA) & Medical Information
South Korea’s law on personal information, considered one of the strictest privacy regulations in the 
world, previously limited the transfer of personal data for research activities including in the medical 
sector. Earlier this year, the National Assembly passed an amendment, allowing pseudonymized data 
sharing with a third party. The amendment goes into effect in August. However, there remains a lack of 
clarity on how data should be pseudonymized and what conditions should be met to utilize data without 
seeking consent from the subject. The issue of medical data generates further ambiguity, as patient 
information, medical records, and such are deemed “sensitive personally identifiable information” which 
cannot be processed. 
Despite these breakthroughs, these laws only set the tone for bio-health innovation. It is essential to scrap 
the current precautionary system and adopt a negative’ risk-based across all stages of development and 
commercialization. 
2. POLICY RECOMMENDATIONS
In 2017, we recommended new legislation that regulate innovative medical devices separately by 
law and introduce fast-track approval systems to enable the rapid advancement of cutting-edge medical 
technologies and new pharmaceuticals. Since then, the National Assembly has passed legislation in line 
with our recommendations. However, the laws have been enacted without fully adopting a “negative” 
regulatory system, which we deemed as the essential force that drives innovation.
Thus we believe, further efforts must be made to scrap ambiguity and risk-averse laws such as those under 
the Bioethics and Safety Act and the Medical Service Act which hinder advancements in bio-health, 
particularly in regenerative medicine and data-driven medicine.
REGENERATIVE MEDICINE
While the recent regulatory changes mentioned above officially categorizes the types of 
regenerative medicine and reorganize regulatory procedures to enable rapid development for treatment, the 
laws continue to impose a positive regulatory system when it comes to human embryo production and 
utilization. Research of embryonic stem cells plays a central role in regenerative medicine and therapeutics, 
and also spans the disciplines of tissue engineering and developmental cell biology.
Thus, in accordance with our previous recommendations, we propose the adoption of the following 
measures on human embryo production and utilization.
First, an act on embryo creation (tentative name) should be enacted to allow the creation of human 
embryonic stem (hES) cells for broader research purposes than advancing fertility, as permitted in the UK. 
There should be no limit to the research purpose or types of diseases to be studied in stem cell research, 
including hES cells. However, the law could ensure research is conducted transparently and ethically by 
clarifying and regulating the terms of registration of the hES, standard procedures, norms for anonymizing 
data and personal information protection, and etc. The UK allows creation of human embryos for the 
procurement of hES cells by law. The original HFE (Human Fertilisation and Embryology) Act allowed 
the creation of embryos in vitro for specific research projects relating to human reproduction and fertility 
but not for other purposes. However, in 2001 the Act was amended to broaden the research use of in vitro 
embryos to include increasing knowledge about embryos, serious and congenital diseases. This enabled the 
HFEA (Human Fertilisation and Embryology Authority) to grant a limited number of laboratories the 
license to culture hES cells for research, a major move committing to the development of regenerative 
medicine (Bryant 2006). 
Box. 1
The UK’s Human Fertilisation and Embryology (HFE) Act, in 1990, established the Human Fertilisation 
and Embryology Authority (HFEA) and outlined its responsibilities which include the regulation of hES 
cell experimentation. The original HFE Act allowed 
The current law under the HFE Act (amended) allows research using and creating human embryos for 
research that relate to one or more of the following purposes: 
• To promote advances in the treatment of infertility
• To increase knowledge about the causes of congenital diseases 
• To increase knowledge about the causes of miscarriage 
• To enhance knowledge in the development of more effective contraception 
• Detection of genetic or chromosomal abnormalities before implantation 
• To increase knowledge about the development of embryos 
• To increase knowledge about serious disease 
• To enable any such knowledge to be applied in developing treatment for serious disease. 
The law also prohibits some key activities:
• The genetic structure of the cell must not be altered while it forms part of an embryo 
• Research embryos must be destroyed on or before 14 days of development 
• No embryo created or used in research may be implanted in a woman (or any animal)
While the law should not limit the purpose or scope of research, it should explicitly prohibit those that raise 
health and safety risks and ethical concerns such as cloning humans, altering the genetic structure of the 
cell while it forms part of an embryo, or implanting embryos used in research in a woman or animal. The 
United States, for instance, has no federal policy on human embryo research, except prohibiting federal 
funding for destroying embryos. By delegating the decision to the state, lawmakers can formulate their own 
policies and strategies based on the general opinion of their constituents. Brazil, China, France, India, and 
Israel also do not impose statutory research restrictions for human embryo research but follow international 
consensus guidelines (Baker Institute). In terms o f following international standards on emerging human 
gene editing tools such as CRISPR-Cas9, the International Summit on Human Genome Editing, under the 
Innovative Genome Institute, gathers global experts to discuss the scientific, ethical, and governance issues 
in such technologies.
Second, open innovation should be encouraged and systematized through legislation, legally 
expanding the scope of actors beyond the few, privileged institutions. Under the Regenerative Medicine 
Act, only a small number of designated hospitals, or “research-focused” hospitals, can conduct R&D in 
regenerative medicine. This effectively excludes other clinicians, researchers and firms from the discovery 
and innovation process. The act should be revised to allow and support all medical actors research, explore 
and develop regenerative medicine. Based on this new framework, the government should foster measures 
to or SMEs, receiving access to workspaces, labs and testing equipment as well as financial support to 
overcome the death valley. In 2012, the UK’s Cell and Gene Catapult, composed of hospital and industry 
experts, academics, researchers and start-ups, formed a cell and gene therapy cluster in Stevenage. Over 
the years, diverse training opportunities, networking events, and support measures and facilities including 
large-scale manufacturing systems have helped small innovators conduct research and bring their therapies 
to market. The ecosystem now hosts 14 companies in the industry, employing more than 350 people and 
raising over £680 million from commercial investors with the purpose of advancing cell and gene therapy. 
The cluster has even attracted GlaxoSmithKline, one of the UK’s two biggest pharma companies, which 
has its research headquarters in Stevenage.  
Instead of aiming to hedge risks and only allowing large hospitals and institutions to explore the 
uncharted waters of regenerative medicine, South Korea should also build an ecosystem that actively 
supports open, and unlimited, innovation. Also, in 2008, we suggested that: in order to facilitate processing 
and utilizing healthcare data to build big data, proper standards of usage, as well as clear and specific 
guidance on deidentification (pseudonymization) and reidentification should be set forth by law (Yu 2018). 
However, the country has been slow to take such measures, and the ambiguity on data usage remains even 
after revising the three data laws, in 2020 as mentioned in the previous chapter. 
HEALTH AND PATIENT DATA
In the age of the Fourth Industrial Revolution, Artificial Intelligence (AI) and other emerging 
technologies are expected to drive new discoveries in medicine and the advancement of medical technology 
from smart health devices that help predict and prevent diseases to treating severe conditions such as cancer 
and organ failure. Fueling this medical revolution is data. From patient information and results of clinical 
trials stored at hospitals to lifelog data collected by wearable devices and smartphone health apps, Clinical 
researchers, physicians and users themselves can benefit from data gathered through physiological and 
biochemical sensors which can aid diagnosis, monitor progress, predict and prevent illness or deterioration 
of health and promptly adjust or update treatments. Digital health solutions are also expected to lower health 
care costs -- both in terms of public funds and also out-of-pocket spending. The UK has been investing 
heavily in Artificial Intelligence in the National Healthcare Service (NHS) to “improve outcomes in the 
NHS and, ultimately, to reduce cost” (Milburn 2020).
In South Korea, there is a great wealth of health data accumulated by the public health insurance 
system, as well as large general hospitals, with the country’s Electronic Medical Records (EMR) adoption 
rate well over 90 percent (Park 2017). Such data could be utilized to improve predictive and preventive 
medical care as well as advance research and development of new drugs and medical innovations. There 
has been a build-up of anticipation on fostering South Korea’s digital bio-health industry, especially with 
the country’s information privacy law (PIPA) being amended to allow pseudonymized information to be 
shared without prior permission. The government has, also, pledged to leverage the country’s massive data 
pool by creating a nationwide health database and encourage data-fuelled innovations to advance the bio-
health sector.  
However, procuring biospecimens and medical information needed for research has been an almost 
impossible feat over the years due to regulations under the Bioethics and Safety Act. First, the Act which 
strictly prohibits the use of such data for both research and commercial purposes, unless the subject of 
research or donor has given written consent which is subsequently reviewed by the Bioethics Committee. 
Second, the specific purpose of research must be written in the consent form, thus making it impossible to 
conduct secondary research beyond the initial purpose in the future. Third, written consent is also required 
for biological or medical information to be provided to another researcher or data bank, as well as 
anonymizing the information. However, it is costly and impractical to track down every donor to get written 
consent every time the biomaterial or information is used in research. Furthermore, even after the process 
of seeking written consent for research as well as anonymization of data, the Bioethics Committee wields 
the power to approve or disapprove the application. Protecting the privacy of patients is essential, of course, 
however, in the context of the medical industry, certain personal attributes need to be identified as every 
patient has different characteristics, health conditions and responses to medicine. Developing new drugs or 
solutions would require crucial personal details in order to enhance the efficacy and safety. Also, a patient’s 
environmental or regional conditions may also affect their health, which would require information such as 
their home address and day-to-day itinerary (Chang 2020). 
In addition, attempts to nurture data-fueled research and application have failed to create a nationwide data 
network, as key information is concentrated in a handful of state-designated hospitals. Permitting only a 
small number of “data-focused” hospitals to leverage patient information has strongly limited the scope of 
innovation in the country, compared to small bio firms and healthcare start-ups in the U.S. and Israel.
To create a leading bio-health industry, fundamental changes are needed to current regulations to 
establish an open innovation system. It is absolutely essential to minimize barriers to sharing data for health 
system management, statistics, research and other health-related purposes that serve the public interest 
while protecting privacy and data security (OECD 2019). Fast regulatory changes and clarification are 
needed to provide guidance to the biohealth industry as the concept and scope of industrial and commercial 
purposes of data usage under PIPA remains ambiguous.
We suggest the following actions:
First, it is imperative to remove excessive restrictions under the Bioethics Act and the oversight of 
the Bioethics Committee. In particular, a separate set of privacy regulations under a special law should 
govern biological and medical information to allow flexibility and creativity in data usage for scientific 
research. If there is a conflict with the Medical Law or Bioethics Law, the Special Law would take 
precedence. 
Second, the processing of sensitive materials and data such as biospecimen and patient information 
should be permitted in research and secondary usage as a general rule, under a broad consent mechanism 
and effective safeguards. As in the United States, South Korea needs to adopt a broad consent system that 
permits researchers to use identifiable biospecimens and data without the requirement to obtain additional 
consent for future storage, maintenance, or research, as long as the future activities are within the scope of 
the initial consent (U.S. Department of Health & Human Services 2017). In order to protect individual 
rights and privacy on personal information, an opt-out mechanism should be put in place, enabling the 
retraction of information upon request. For instance, the UK’s National Health Service (NHS), in 2018, 
introduced a system that allows patients to “opt out” of their confidential information being used in research. 
However, this also means their information can be used in research by default, unless they explicitly decide 
against it. 
Personal Information Protection Act (PIPA) 
PIPA was recently revised to allow pseudonymized information to be used without consent for research 
purposes. However, while most personal information or financial information such as social security 
numbers and phone numbers are composed of text and digits, biological and medical information are 
categorized as “sensitive personal information” derived from a person's unique physical and behavioral 
characteristics such as a fingerprint, signature, vein pattern, face, voice, iris, and DNA. Thus, the 
Bioethics Act has been the  
(Article 2, 17 and 18 of the Bioethics Act)
Third, new legislation is needed to promote active sharing and exchange of biospecimens and data 
across medical actors including hospitals, clinics, research centers and private institutions, allowing them 
to request and receive data upon request.  Data sharing has become vital in novel clinical trials to assess the 
efficacy and safety of emerging therapies and diagnostics. 
Currently, the use of health and patient information is limited to state-designated institutions, which are 
mostly large, university hospitals. Since 2018, South Korea has allowed only 39 hospitals to utilize medical 
data in research and the development of new treatments, drugs, medical solutions and technologies. The 
government aims to select five more “data-focused” hospitals in 2020. However, limiting the number of 
players has led to the monopolization of patient data. Our interviews with regulatory and medical experts 
have found large hospitals tend to be reluctant to share their data or other such vital information with other 
institutions. This effectively hinders the growth of an ecosystem of collaboration and open innovation.
At present, there is no law that permits sensitive information from public and private medical institutions 
to be shared or integrated for the purpose of clinical research (Personal Information Protection Commission 
2016), however this mechanism is essential -- from gaining deep insights and new knowledge to developing 
breakthrough medical treatments and optimizing services to provide personalized, quality health care. Thus 
we suggest data be combined through a nationally-designated institution equipped with adequate security 
facilities.
Also, revisions should be made to the Medical Services Act which currently limits the management of 
patient records, including electronic medical records (EMR), to medical personnel and institutions. We 
propose that individuals and firms providing health-related services should also be allowed to collect, 
manage and exchange health and biometric information from electronic devices, and even combine 
different information from other platforms and devices to gain new, holistic insights on patients’ health. In 
the U.S., health planning companies are helping digital health start-ups test their products in real-world 
clinical environments by providing access to de-identified data on 4.5 million of their members across three 
states. Also, bioinformatics companies can develop software and algorithms that help companies optimize 
the quality of their data in next generation sequencing (NGS), for instance. These services would not only 
benefit developers, but also provide a whole new market for start-ups and SMEs to develop bioinformatics 
solutions, as software does not require as much heavy research and investment as other areas of biotech. 
Furthermore, a clear national mechanism should be established to set a common, compatible 
standard for medical data use, storage, transfer, and protection, using technologies such as blockchain. Data-
focused hospitals in South Korea have developed their own standards, tools and software to collect and 
make use of biospecimen and patient data, meaning they are not compatible with platforms in other medical 
institutions. Thus, by setting standards to ensure the optimal quality, accessibility and interoperability of 
patient and health data across diverse medical organizations, data can be better managed, utilize and 
protected. Blockchain could facilitate verified access to EHRs, by medical institutions and researchers, 
securing and tracking each “transaction” transparently, all the while allowing data subjects control over 
their information and verify how it is shared (Pauwels and Grevatt 2017). 
Also, misuse or unauthorized access to data should be clearly defined and also be subject to stronger 
punishment. This is particularly important in digital health technologies and services, especially 
telemedicine. Over the last decade, the use of telemedicine has grown significantly throughout the world as 
an effective, accessible form of healthcare, especially in countries with burgeoning elderly populations and 
an increasing burden on the public health insurance system. There has also been growing interest in remote 
consultations and therapy, as most of the world’s population are becoming more and more comfortable with 
using digital solutions than making in-person appointments. While doctor-patient telemedicine is banned 
in South Korea, under Article 34 of the Medical Act, the need for remote medical services was further 
highlighted by the coronavirus pandemic, with government authorities temporarily allowing phone 
consultations between doctors and patients to reduce risk of infection. South Korea’s Centers for Disease 
Control and Prevention said there were 242 cases of phone consultations until March 10th and a survey of 
906 remote patients found 87 percent were satisfied with the services. However, attempts to adopt 
telemedicine by the government has been thwarted by fierce opposition by mostly small clinicians and civic 
groups. It is essential to address the issue of liability, as well as set standards on clinical protocol, safety 
measures and patient data management to help mitigate the biggest concerns surrounding telemedicine in 
the country. 
Fifth, various initiatives are needed to strengthen public awareness and determine the level of social 
consensus on data and privacy. Generally speaking, in the South Korean society, there is distrust towards 
the adoption and governance of new technologies and the fairness in distributing the benefits of innovation. 
This low level of social credibility adversely affects social acceptance of the data and AI-based bioeconomy, 
while creating an environment that hinders the spread of innovation outcomes and benefits across society. 
Therefore, in order to bolster the data-AI-based bioeconomy, it is very important to actively promote social 
acceptance by increasing social credibility in the following ways (Choi 2019):
From the perspective of consumers, it is necessary to reinforce awareness of the public interest and 
social values of biodata and bioeconomy, and to create a legal and institutional environment that emboldens 
citizens' right to self-determination about health and medical information. The biohealth ecosystem, in 
which biodata determines competitiveness, has insurmountable potential to advance public interest and 
social value because it is directly connected to human health and life. In addition, public initiatives should 
aim to achieve an overall culture change in sharing biomaterial and information, empowering citizens to 
exert their ownership and control over their data for the advancement of public health and science, 
benchmarking the UK, US and Canada’s ‘Personal Genome Project’ which encourages individuals to share 
their genomic data, traits and cells for free to create a global database for research. 
In Korea, public institutions such as the National Health Insurance Corporation hold a great volume of 
patient data, so the possibility of creating public interest and social value through utilization is also very 
high. Therefore, if people become more aware of the value of their data and the right to control and 
contribute their health information, the bio ecosystem would be greatly bolstered.
Next, it is necessary to provide policy support to boost the credibility of the data handling system 
which is critically lacking in public trust. For this, the distribution structure of benefits that arise from using 
biodata must be established clearly and fairly with the purpose of promoting and advancing public health 
and well-being. If data suppliers including patients and health service users trust that the distribution of 
benefits is fair, they would actively contribute and allow the sharing of more data, thereby increasing 
individual consumer utility as well as advancing public health for society as a whole. 
Furthermore, the government should refine and strengthen its mediating role between interested 
parties such as the medical, industrial, and civil society organizations, and build the credibility of policies 
and enforcement. Even though nearly eight in ten citizens surveyed were in favor of using personal biodata
for public interest, only eight percent trust the ‘government’s policies and societal system.’ Most were 
hesitant due to concerns about the fairness of penalties and punishment upon misuse or breaches of data 
and were sceptical about the distribution of benefits. Thus, it is very important to establish a balanced 
protection policy system that supports fair and safe sharing and use of biodata, all the while promoting 
effective utilization.
South Korea’s bio-health sector stands at a critical inflection point. Through reflexive regulatory 
reform, the country must act quickly to harness its strengths in digital infrastructure, hospital networks, data 
and skilled medical personnel while overcoming barriers to R&D and innovation. The prospects are bright 
but fundamental changes are crucially needed.
CHAPTER 4: CONCLUSION & DISCUSSION
South Korea is endowed with a state-of-the-art industrial landscape, boasting of the latest 
infrastructure and world-class research facilities. The top-level hardware, however, continues to operate on 
a software designed for industries of the past, retaining the fundamental spirit of regulatory restrictions, risk 
averse culture, and a lack of social dialogue and democracy on adopting new technologies. An innovation 
ecosystem is long overdue, yet the government’s key economic strategy maintains the top-down model of 
growth that is well past its sell-date. The Korean New Deal Strategy is largely focused on state-led job 
creation and expansion of public services, investing which will create 1.9 million jobs by investing a total 
of KRW 160 trillion ($133.1 billion) by 2025. The proposed budget for 2021 injects KRW 30.6 trillion in 
job creation, an annual increase of 20 percent, while spending only KRW 27 trillion in R&D and cutting 
expenditure in Education by 2 percent. Meanwhile, genuine social needs for innovation in areas like 
telemedicine and data-based technologies continue to be unmet. For South Korea to make meaningful 
progress toward sustainable growth as an advanced economy and society, it must take the leap to become 
an entrepreneurial state through greater support and incentives for research and education, and a society-
wide innovation ecosystem, rather than rely on shot-in-the-arm solutions.
Thus, the measures we proposed for South Korea in 2018 remain consistent today (Lee J. and Choi 
C. 2018), but the need to adopt a bottom-up ecosystem is now more pressing than ever. In fact, as a growing 
number of countries actively adopt and overtake South Korea in designing new regulatory frameworks to 
accommodate Industry 4.0, our suggested measures stated below can be followed as a guideline in other 
jurisdictions.
First, the government must quickly identify and remove red tape by streamlining existing 
regulations and regulatory authorities. Regulatory overlaps, overcomplicated procedures, and the common
top-down mode of governance commonly found in bureaucracy often slows or even stifles innovative 
activities, especially the development of new products and services. This dampens sustainability and growth 
for research and business alike, especially for those operating on a smaller capacity as they do not have the 
resources to work through time-consuming and financially exhausting approval procedures, or other such 
regulatory barriers. Thus, an integrated regulatory system should provide clear and common guidelines, 
grounds, provisions, and mechanisms to minimize confusion and hindrances for key developers of emerging 
technologies. Furthermore, it is worth considering additional measures to remove jurisdictional conflicts as 
well as micromanagement on R&D activities. 
Second, scientists and researchers should have a greater voice in each stage of regulatory design, 
participating in key bodies and platforms for regulatory reform on R&D. We proposed the establishment 
of a separate council dedicated to the task, where field researchers actively participate and contribute their 
expertise. The body should evaluate regulatory impact, deliberate new regulations, and amend or scrap 
existing regulations. In order to create the optimal environment for innovative R&D, the input of field 
experts with first-hand knowledge and experience is vital as they can offer deep insights and practical 
solutions. Also, as they are likely to promote and adopt industry standards, such regulations would be better 
received and followed by the scientific community, increasing positive outcomes and reducing compliance 
costs.
Third, regulatory power should be expanded and delegated to standard-setting organisations and 
research institutes in science and technology. Industry-defined standards can allow for self-regulation, 
aiding better compliance and performance among the players. Self-regulation and oversight can typically 
be conducted in research ethics (such as standards on academic integrity, plagiarism, records of data and 
cited information, and etc.) as well as research expenses and management. These regulations tend to be 
based on sub-administration rules or regulations, rather than statutes, so few legal issues would arise from 
the delegation of regulatory authority. Science and technology is, in fact, a field in which industry standards 
are commonly used, and it is comparatively easier for the members to establish a consensus among the 
members. This could enable the science and tech industry to, further, develop and abide by its own 
guidelines on social and ethical issues, in a form of self-regulation. For instance, the UK’s General Medical 
Council (GMC), a regulatory body for medical practitioners, is responsible for developing standards in 
education and training, as well as codes of conduct and investigating patient concerns. The council was 
delegated the responsibility of standard-setting, as the highly-specialized, technical nature of the profession 
requires significant area-specific expertise (UK Dept for Industry Strategy 2019). 
Fourth, ethical standards must be developed and rationalized by social consensus. As ethics is a 
social construct, it is crucial to include and heed public opinion as the Fourth Industrial Wave not only 
causes technological changes but also disrupts societal order and gives rise to unprecedented ethical 
challenges. This is in line with the principle of deliberative democracy that encourages the collective 
intelligence of ordinary citizens and facilitates public awareness, allowing for social problem-solving. In 
doing so, it is essential to overcome the information asymmetry that exists between experts, governments, 
and citizens and promote well-informed opinions. In this regard, citizens must have access to sufficient and 
accurate information on the issue at hand which should be presented transparently as informational content 
and audio-visual materials through various formats, such as storytelling, narratives, and entertainment 
content. Furthermore, to reflect public opinion in regulatory discourse, opinion surveys and social media 
platforms for dialogue are possible tools that could be utilized. 
Going forward, open innovation cannot occur without a system-wide change that involves all actors 
of society. Governments must reform themselves from being rigid, formalistic, authoritative, and 
excessively controlling bureaucracies, to flexible and adaptive enablers of innovation. Authorities should 
commit to the spirit of civil servanthood and mediating the innovation process, both accommodating and 
keeping in check researchers and corporations, as well as encouraging citizen participation in deliberating 
regulations (Lee J. and Choi C., 2018).  Meanwhile, for industry and academia, their propensity to avoid or 
minimize risk and responsibility should be replaced with risk-taking, forward-thinking mindsets that are 
strongly geared towards social objectives. Lastly, and most crucially, citizens must make the shift from 
being mere consumers to becoming active contributors that shape and regulate disruptive technologies. 
It is clear that the top-down system of regulation that governed the previous industrial era is no 
longer relevant today nor can it support sustainable growth in the modern world economy. The first step in 
the path of innovation must be taken together by all stakeholders to harness the waves of changes of the 
Fourth Industrial Revolution, and make the leap from fast-follower to first mover amid the rapidly changing 
dynamics of the global economy.
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